Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Revolution Medicines publishes data on mTORC1-selective inhibitors » 16:08
06/24/21
06/24
16:08
06/24/21
16:08
RVMD

Revolution Medicines

$32.61 /

-0.24 (-0.73%)

Revolution Medicines…

Revolution Medicines announced the publication of an original scientific paper in Nature Chemical Biology describing anti-tumor effects of bi-steric mTORC1-selective inhibitors that potently suppress phosphorylation of 4EBP1, a translational regulator of oncogene expression. In preclinical models of cancers with mutations that drive mTORC1 hyperactivation, a series of bi-steric inhibitors demonstrated the favorable anti-tumor effects and tolerability of deeply and selectively inhibiting mTORC1 compared to earlier generations of mTOR inhibitors. Mutations that cause hyperactive mTORC1 signaling are found in tumors with and without co-existent RAS mutations. This original research was led by scientists at Revolution Medicines and conducted in collaboration with the Neal Rosen Lab at the Memorial Sloan Kettering Cancer Center, as well as researchers from McGill University and The Karolinska Institute. Revolution Medicines recently advanced RMC-5552, the company's investigational first-in-class bi-steric mTORC1 inhibitor, into clinical development. RMC-5552 is a potent and selective inhibitor of mTORC1 that is being developed as an anti-cancer therapeutic for patients with solid tumors that exhibit hyperactivation of the mTOR pathway, including certain RAS-addicted cancers. The compound is designed to inhibit mTORC1 and thereby protect the natural tumor suppressor activity of 4EBP1, without the undesirable inhibition of mTORC2. RMC-5552 has demonstrated anti-tumor activity in a wide variety of preclinical models. Revolution Medicines has also reported in vivo data demonstrating that RMC-5552 may increase anti-tumor activity in combination with KRASG12C inhibitors in lung and colon cancers harboring both KRAS mutations and co-mutations in the mTOR signaling pathway that can cause resistance to single agent RAS inhibition.

ShowHide Related Items >><<
RVMD Revolution Medicines
$32.61 /

-0.24 (-0.73%)

RVMD Revolution Medicines
$32.61 /

-0.24 (-0.73%)

05/18/21 Goldman Sachs
Revolution Medicines initiated with a Buy at Goldman Sachs
05/11/21 SVB Leerink
Revolution Medicines price target lowered to $46 from $55 at SVB Leerink
03/03/21 SVB Leerink
Revolution Medicines price target raised to $55 from $46 at SVB Leerink
01/29/21 JPMorgan
Revolution Medicines price target raised to $44 from $33 at JPMorgan
RVMD Revolution Medicines
$32.61 /

-0.24 (-0.73%)

  • 04
    Feb
  • 09
    Jul
RVMD Revolution Medicines
$32.61 /

-0.24 (-0.73%)

Conference/Events
Revolution Medicines to hold a conference call » 15:45
06/17/21
06/17
15:45
06/17/21
15:45
RVMD

Revolution Medicines

$33.87 /

-0.93 (-2.67%)

Chairman & CEO…

Chairman & CEO Goldsmith and President of Research & Development Kelsey hold a conference call to provide a perspective on emerging insights about RAS-addicted cancers and implications of common drug resistance mechanisms on June 17 at 4 pm. Webcast Link

ShowHide Related Items >><<
RVMD Revolution Medicines
$33.87 /

-0.93 (-2.67%)

RVMD Revolution Medicines
$33.87 /

-0.93 (-2.67%)

05/18/21 Goldman Sachs
Revolution Medicines initiated with a Buy at Goldman Sachs
05/11/21 SVB Leerink
Revolution Medicines price target lowered to $46 from $55 at SVB Leerink
03/03/21 SVB Leerink
Revolution Medicines price target raised to $55 from $46 at SVB Leerink
01/29/21 JPMorgan
Revolution Medicines price target raised to $44 from $33 at JPMorgan
RVMD Revolution Medicines
$33.87 /

-0.93 (-2.67%)

  • 04
    Feb
  • 09
    Jul
RVMD Revolution Medicines
$33.87 /

-0.93 (-2.67%)

Conference/Events
Revolution Medicines to hold a conference call » 04:55
06/17/21
06/17
04:55
06/17/21
04:55
RVMD

Revolution Medicines

$34.75 /

+0.73 (+2.15%)

Chairman & CEO…

Chairman & CEO Goldsmith and President of Research & Development Kelsey hold a conference call to provide a perspective on emerging insights about RAS-addicted cancers and implications of common drug resistance mechanisms on June 17 at 4 pm. Webcast Link

ShowHide Related Items >><<
RVMD Revolution Medicines
$34.75 /

+0.73 (+2.15%)

RVMD Revolution Medicines
$34.75 /

+0.73 (+2.15%)

05/18/21 Goldman Sachs
Revolution Medicines initiated with a Buy at Goldman Sachs
05/11/21 SVB Leerink
Revolution Medicines price target lowered to $46 from $55 at SVB Leerink
03/03/21 SVB Leerink
Revolution Medicines price target raised to $55 from $46 at SVB Leerink
01/29/21 JPMorgan
Revolution Medicines price target raised to $44 from $33 at JPMorgan
RVMD Revolution Medicines
$34.75 /

+0.73 (+2.15%)

  • 04
    Feb
  • 09
    Jul
RVMD Revolution Medicines
$34.75 /

+0.73 (+2.15%)

Conference/Events
Revolution Medicines to hold a conference call » 15:33
06/10/21
06/10
15:33
06/10/21
15:33
RVMD

Revolution Medicines

$33.68 /

+1.01 (+3.09%)

Chairman & CEO…

Chairman & CEO Goldsmith and President of Research & Development Kelsey hold a conference call to provide a perspective on emerging insights about RAS-addicted cancers and implications of common drug resistance mechanisms on June 17 at 4 pm. Webcast Link

ShowHide Related Items >><<
RVMD Revolution Medicines
$33.68 /

+1.01 (+3.09%)

RVMD Revolution Medicines
$33.68 /

+1.01 (+3.09%)

05/18/21 Goldman Sachs
Revolution Medicines initiated with a Buy at Goldman Sachs
05/11/21 SVB Leerink
Revolution Medicines price target lowered to $46 from $55 at SVB Leerink
03/03/21 SVB Leerink
Revolution Medicines price target raised to $55 from $46 at SVB Leerink
01/29/21 JPMorgan
Revolution Medicines price target raised to $44 from $33 at JPMorgan
RVMD Revolution Medicines
$33.68 /

+1.01 (+3.09%)

  • 04
    Feb
  • 09
    Jul
RVMD Revolution Medicines
$33.68 /

+1.01 (+3.09%)

Hot Stocks
Revolution Medicines to host webcast on studies of RAS inhibitors » 07:46
06/10/21
06/10
07:46
06/10/21
07:46
RVMD

Revolution Medicines

$32.74 /

+0.47 (+1.46%)

Revolution Medicines…

Revolution Medicines announced that it will host a Science Talk webcast to highlight learnings from recent preclinical and clinical studies of RAS inhibitors. The webcast, to be held at 4:00 p.m. Eastern on June 17, 2021, will provide a perspective on emerging insights about RAS-addicted cancers, including the implications of common drug resistance mechanisms on targeted treatment strategies. The presentation will be led by Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman, and Steve Kelsey, M.D., president, research and development. During the event, Drs. Kelsey and Goldsmith will discuss scientific data from the field reported in the first half of 2021 relating to oncogenic RAS signaling, identification of cellular mechanisms that drive resistance to targeted RAS inhibitors, and treatment advances, limitations and new opportunities. Material will include clinical and preclinical findings reported by the company and other investigators at the 2021 American Association for Cancer Research Virtual Annual Meeting, published work, and additional unreported observations regarding compounds from its RAS Inhibitor and RAS Companion Inhibitor portfolios.

ShowHide Related Items >><<
RVMD Revolution Medicines
$32.74 /

+0.47 (+1.46%)

RVMD Revolution Medicines
$32.74 /

+0.47 (+1.46%)

05/18/21 Goldman Sachs
Revolution Medicines initiated with a Buy at Goldman Sachs
05/11/21 SVB Leerink
Revolution Medicines price target lowered to $46 from $55 at SVB Leerink
03/03/21 SVB Leerink
Revolution Medicines price target raised to $55 from $46 at SVB Leerink
01/29/21 JPMorgan
Revolution Medicines price target raised to $44 from $33 at JPMorgan
RVMD Revolution Medicines
$32.74 /

+0.47 (+1.46%)

  • 04
    Feb
  • 09
    Jul
RVMD Revolution Medicines
$32.74 /

+0.47 (+1.46%)

Initiation
Revolution Medicines initiated with a Buy at Goldman Sachs » 05:53
05/18/21
05/18
05:53
05/18/21
05:53
RVMD

Revolution Medicines

$31.40 /

-0.52 (-1.63%)

Goldman Sachs analyst…

Goldman Sachs analyst Chris Shibutani initiated coverage of Revolution Medicines with a Buy rating and $49 price target. The analyst believes the company's RAS(ON) platform offers a differentiated approach to expand direct RAS inhibition beyond KRAS G12C. Shibutani projects $1.2B in risk-adjusted 2030 peak sales.

ShowHide Related Items >><<
RVMD Revolution Medicines
$31.40 /

-0.52 (-1.63%)

RVMD Revolution Medicines
$31.40 /

-0.52 (-1.63%)

05/11/21 SVB Leerink
Revolution Medicines price target lowered to $46 from $55 at SVB Leerink
03/03/21 SVB Leerink
Revolution Medicines price target raised to $55 from $46 at SVB Leerink
01/29/21 JPMorgan
Revolution Medicines price target raised to $44 from $33 at JPMorgan
10/26/20 H.C. Wainwright
Revolution Medicines price target raised to $54 from $52 at H.C. Wainwright
RVMD Revolution Medicines
$31.40 /

-0.52 (-1.63%)

  • 04
    Feb
  • 09
    Jul
RVMD Revolution Medicines
$31.40 /

-0.52 (-1.63%)

RVMD Revolution Medicines
$31.40 /

-0.52 (-1.63%)

Recommendations
Revolution Medicines price target lowered to $46 from $55 at SVB Leerink » 09:15
05/11/21
05/11
09:15
05/11/21
09:15
RVMD

Revolution Medicines

$29.79 /

+0.33 (+1.12%)

SVB Leerink analyst…

SVB Leerink analyst Jonathan Chang lowered the firm's price target on Revolution Medicines to $46 from $55 and keeps an Outperform rating on the shares after the company reported Q1 financial results and provided a pipeline update that was in line with expectations. While the RAS pathway drug development landscape is highly competitive, Chang believes Revolution Medicines has a differentiated approach and the scientific ability to solve the challenging targets.

ShowHide Related Items >><<
RVMD Revolution Medicines
$29.79 /

+0.33 (+1.12%)

RVMD Revolution Medicines
$29.79 /

+0.33 (+1.12%)

03/03/21 SVB Leerink
Revolution Medicines price target raised to $55 from $46 at SVB Leerink
01/29/21 JPMorgan
Revolution Medicines price target raised to $44 from $33 at JPMorgan
10/26/20 H.C. Wainwright
Revolution Medicines price target raised to $54 from $52 at H.C. Wainwright
09/14/20 Jefferies
Inhibrx initiated with a Buy at Jefferies
RVMD Revolution Medicines
$29.79 /

+0.33 (+1.12%)

  • 04
    Feb
  • 09
    Jul
RVMD Revolution Medicines
$29.79 /

+0.33 (+1.12%)

RVMD Revolution Medicines
$29.79 /

+0.33 (+1.12%)

Earnings
Revolution Medicines reports Q1 EPS (53c), consensus (52c) » 16:36
05/10/21
05/10
16:36
05/10/21
16:36
RVMD

Revolution Medicines

$29.79 /

+0.33 (+1.12%)

Reports Q1 revenue…

Reports Q1 revenue $10.13M, consensus $9.46M. Cash, cash equivalents and marketable securities were $681.6M as of March 31, compared to $440.7M as of December 31, 2020. The increase was primarily due to proceeds from the company's equity public offering in February. "Revolution Medicines has made excellent progress reinforcing our belief that the company's cohesive portfolio of innovative clinical and preclinical assets will power compelling rational, mechanism-based combination treatments that provide benefit to patients with RAS-addicted cancers," said Mark Goldsmith, CEO and chairman of Revolution Medicines.

ShowHide Related Items >><<
RVMD Revolution Medicines
$29.79 /

+0.33 (+1.12%)

RVMD Revolution Medicines
$29.79 /

+0.33 (+1.12%)

03/03/21 SVB Leerink
Revolution Medicines price target raised to $55 from $46 at SVB Leerink
01/29/21 JPMorgan
Revolution Medicines price target raised to $44 from $33 at JPMorgan
10/26/20 H.C. Wainwright
Revolution Medicines price target raised to $54 from $52 at H.C. Wainwright
09/14/20 Jefferies
Inhibrx initiated with a Buy at Jefferies
RVMD Revolution Medicines
$29.79 /

+0.33 (+1.12%)

  • 04
    Feb
  • 09
    Jul
RVMD Revolution Medicines
$29.79 /

+0.33 (+1.12%)

RVMD Revolution Medicines
$29.79 /

+0.33 (+1.12%)

Hot Stocks
Revolution Medicines highlights board of directors nominees for upcoming meeting » 07:27
05/03/21
05/03
07:27
05/03/21
07:27
RVMD

Revolution Medicines

$33.40 /

-1.58 (-4.52%)

Revolution Medicines…

Revolution Medicines highlights the nomination of a slate of three individuals for election/reelection to its board of directors. Flavia Borellini, Ph.D. has been nominated by the company's board of directors for election as a first-time Class I director, joining current Class I directors Elizabeth McKee Anderson and Neil Exter, who were nominated for reelection. These nominees will be voted on at the June 22, 2021 Revolution Medicines annual meeting of stockholders. Borellini has more than 25 years of executive management experience in the pharmaceutical and biotechnology industry. She is the former CEO for Acerta Pharma. Anderson has been a member of the Revolution Medicines board of directors since 2015. Exter, a member of Revolution Medicines board from 2014 to 2016 and since 2019, has served as a partner of Third Rock Ventures for nearly 15 years. In related news, Peter Svennilson will no longer serve as a director after completion of his term at the company's annual meeting of stockholders.

ShowHide Related Items >><<
RVMD Revolution Medicines
$33.40 /

-1.58 (-4.52%)

RVMD Revolution Medicines
$33.40 /

-1.58 (-4.52%)

03/03/21 SVB Leerink
Revolution Medicines price target raised to $55 from $46 at SVB Leerink
01/29/21 JPMorgan
Revolution Medicines price target raised to $44 from $33 at JPMorgan
10/26/20 H.C. Wainwright
Revolution Medicines price target raised to $54 from $52 at H.C. Wainwright
09/14/20 Jefferies
Inhibrx initiated with a Buy at Jefferies
RVMD Revolution Medicines
$33.40 /

-1.58 (-4.52%)

  • 04
    Feb
  • 09
    Jul
RVMD Revolution Medicines
$33.40 /

-1.58 (-4.52%)

RVMD Revolution Medicines
$33.40 /

-1.58 (-4.52%)

Over a quarter ago
Hot Stocks
Revolution Medicines does not expect RMC-4630, sotorasib data in 2021 » 07:19
04/30/21
04/30
07:19
04/30/21
07:19
RVMD

Revolution Medicines

$34.98 /

+1.16 (+3.43%)

, AMGN

Amgen

$234.68 /

-2.06 (-0.87%)

Revolution Medicines…

Revolution Medicines (RVMD) said that after consultation with Amgen (AMGN), it is providing an update to investors regarding the Amgen-sponsored Phase 1b study of RMC-4630 in combination with Amgen's KRASG12C inhibitor, AMG 510 or sotorasib, as part of Amgen's CodeBreak 101 study. To date, the available data from the RMC-4630 and sotorasib combination in this ongoing study has "demonstrated acceptable tolerability and cleared early dose levels," the company said in a regulatory filing. Amgen's CodeBreaK 101c study is currently dosing patients at the RMC-4630 target dose of 200 mg on a Day 1/Day 2 weekly schedule. Revolution said it "looks forward to selection of a combination dose in the second half of 2021." The company does not currently expect clinical data from the RMC-4630 and sotorasib combination to be provided in 2021. Revolution expects Amgen, as sponsor of this study, to report data from CodeBreaK 101c at a future date to be determined at Amgen's discretion.

ShowHide Related Items >><<
RVMD Revolution Medicines
$34.98 /

+1.16 (+3.43%)

AMGN Amgen
$234.68 /

-2.06 (-0.87%)

RVMD Revolution Medicines
$34.98 /

+1.16 (+3.43%)

03/03/21 SVB Leerink
Revolution Medicines price target raised to $55 from $46 at SVB Leerink
01/29/21 JPMorgan
Revolution Medicines price target raised to $44 from $33 at JPMorgan
10/26/20 H.C. Wainwright
Revolution Medicines price target raised to $54 from $52 at H.C. Wainwright
09/14/20 Jefferies
Inhibrx initiated with a Buy at Jefferies
AMGN Amgen
$234.68 /

-2.06 (-0.87%)

04/28/21 Atlantic Equities
Amgen downgraded to Underweight from Neutral at Atlantic Equities
04/28/21 Credit Suisse
Amgen price target lowered to $259 from $265 at Credit Suisse
04/28/21 BMO Capital
Amgen price target lowered to $296 from $301 at BMO Capital
04/28/21 Piper Sandler
Piper Sandler cuts Amgen target to $255 after 'ugly' quarter
RVMD Revolution Medicines
$34.98 /

+1.16 (+3.43%)

AMGN Amgen
$234.68 /

-2.06 (-0.87%)

  • 04
    Feb
  • 09
    Jul
AMGN Amgen
$234.68 /

-2.06 (-0.87%)

RVMD Revolution Medicines
$34.98 /

+1.16 (+3.43%)

AMGN Amgen
$234.68 /

-2.06 (-0.87%)

RVMD Revolution Medicines
$34.98 /

+1.16 (+3.43%)

AMGN Amgen
$234.68 /

-2.06 (-0.87%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.